Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome
This study has been completed.
Study NCT00270452   Information provided by National Institutes of Health Clinical Center (CC)

First Received on December 24, 2005.   Last Updated on March 14, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndrome (MDS)
Additional conditions recognized in this trial
Myelodysplastic Syndromes
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Precancerous Conditions
Interventions listed in this trial
WT1 and PR1 Peptide Vaccine
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services